Ricerca
La reidratazione orale e l’uso dell’ondansetron e del domperidone nella gastroenterite
Oral rehydration and the use of ondansetron and of domperidone in acute gastroenteritis: an italian multicentric trial
F. Marchetti, M. Bonati, A. Maestro, D. Zanon, F. Rovere, A. Arrighini, E. Barbi, P. Bertolani, P. Biban, L. Da Dalt, A. Guala, E. Mazzoni, A. Pazzaglia, P.F. Perri, A. Reale, S. Renna, A.F. Urbino, E. Valletta, A. Vitale, T. Zangardi, A. Clavenna, L. Ronfani, a nome del Gruppo di Studio SONDO (Studio ONdansetron vs DOmperidone)
Gennaio 2017 - pagg. 21 -29
Abstract
Background - Vomiting limits the success of oral rehydration in children with acute gastroenteritis (AGE). A double-blind randomized trial was conducted to compare the efficacy of ondansetron and domperidone for the symptomatic treatment of vomiting in children with AGE who have failed oral rehydration.
Methods - After failure of initial oral rehydration administration, children aged 1-6 years admitted for gastroenteritis to the paediatric emergency units of 15 hospitals in Italy were randomized to receive one oral dose of ondansetron (0.15 mg/kg) or domperidone (0.5 mg/kg) or placebo. The primary outcome was the percentage of children receiving nasogastric or intravenous rehydration.
Results - 1313 children were eligible for the first attempt with oral rehydration solution, which was successful for 832 (63.4%); 356 underwent randomization: 118 to placebo, 119 to domperidone, and 119 to ondansetron. Fourteen (11.8%) needed intravenous rehydration in the ondansetron group vs 30 (25.2%) and 34 (28.8%) in the domperidone and placebo groups, respectively. Ondansetron reduced the risk of intravenous rehydration by over 50%, both vs placebo (RR 0.41, 98.6% CI 0.20-0.83) and domperidone (RR 0.47, 98.6% CI 0.23-0.97). No differences for adverse events were seen among groups.
Conclusions - In a context of emergency care, 6 out of 10 children aged 1-6 years with vomiting due to gastroenteritis and without severe dehydration can be managed effective- ly with the administration of oral rehydration solution alone. In children who fail oral rehydration, a single dose of oral ondansetron reduces vomiting and facilitates oral rehydration and may thus be well suited for use in the emergency department. Domperidone was not effective for the symptomatic treatment of vomiting during acute gastroenteritis.
Methods - After failure of initial oral rehydration administration, children aged 1-6 years admitted for gastroenteritis to the paediatric emergency units of 15 hospitals in Italy were randomized to receive one oral dose of ondansetron (0.15 mg/kg) or domperidone (0.5 mg/kg) or placebo. The primary outcome was the percentage of children receiving nasogastric or intravenous rehydration.
Results - 1313 children were eligible for the first attempt with oral rehydration solution, which was successful for 832 (63.4%); 356 underwent randomization: 118 to placebo, 119 to domperidone, and 119 to ondansetron. Fourteen (11.8%) needed intravenous rehydration in the ondansetron group vs 30 (25.2%) and 34 (28.8%) in the domperidone and placebo groups, respectively. Ondansetron reduced the risk of intravenous rehydration by over 50%, both vs placebo (RR 0.41, 98.6% CI 0.20-0.83) and domperidone (RR 0.47, 98.6% CI 0.23-0.97). No differences for adverse events were seen among groups.
Conclusions - In a context of emergency care, 6 out of 10 children aged 1-6 years with vomiting due to gastroenteritis and without severe dehydration can be managed effective- ly with the administration of oral rehydration solution alone. In children who fail oral rehydration, a single dose of oral ondansetron reduces vomiting and facilitates oral rehydration and may thus be well suited for use in the emergency department. Domperidone was not effective for the symptomatic treatment of vomiting during acute gastroenteritis.
Suggerite dall'AI
Classificazione MeSH
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
1. Malek MA, Curns AT, Holman RC, et al.
Diarrhea and rotavirus-associated hospitalizations
among children less than 5 years of age:
United States, 1997 and 2000. Pediatrics 2006;
117:1887-92.
2. Van Damme P, Giaquinto C, Huet F,
Gothefors L, Maxwell M, Van der Wielen M.
Multicenter prospective study of the burden
of rotavirus acute gastroenteritis in Europe,
2004±2005: the REVEAL study. J Infect Dis
2007;195(Suppl 1):S4-S16.
3. Soriano-Gabarṛ M, Mrukowicz J, Vesikari
T, Verstraeten T. Burden of rotavirus disease
in European Union countries. Pediatr Infect
Dis J 2006;25:S7-S11.
4. Guarino A, Ashkenazi S, Gendrel D, Vecchio
AL, Shamir R, Szajewska H. European Society
for Paediatric Gastroenterology, Hepatology,
and Nutrition/European Society for Paediatric
Infectious Diseases Evidence-based Guidelines
for the Management of Acute Gastroenteritis
in Children in Europe: Update 2014. J Pediatr
Gastroenterol Nutr 2014;59:132-52.
5. King CK, Glass R, Bresee JS, Duggan C;
Centers for Disease Control and Prevention.
Managing acute gastroenteritis among children:
oral rehydration, maintenance, and nutritional
therapy. MMWR Recomm Rep 2003;
52(RR-16):1-16.
6. Khanna R, Lakhanpaul M, Burman-Roy S,
Murphy MS; Guideline Development Group
and the technical team. Diarrhoea and vomiting
caused by gastroenteritis in children under
5 years: summary of NICE guidance. BMJ
2009;25:1009-12.
7. Cheng A. Emergency department use of oral
ondansetron for acute gastroenteritis-related
vomiting in infants and children. Paediatr
Child Health 2011;16:177-82.
8. Ozuah PO, Avner JR, Stein RE. Oral rehydration,
emergency physicians, and practice
parameters: a national survey. Pediatrics 2002;
109:259-61.
9. Karpas A, Finkelstein M, Reid S. Parental
preference for rehydration method for children
in the emergency department. Pediatr Emerg
Care 2009;25:301-6.
10. Albano F, Bruzzese E, Spagnuolo MI, De
Marco G. Antiemetics for children with gastroenteritis:
off label but still on in clinical
practice. J Pediatr Gastroenterol Nutr 2006;43:
402-4.
11. Zanon D, Gallelli L, Rovere F, et al. Off-label
prescribing patterns of antiemetics in children:
a multicenter study in Italy. Eur J Pediatr
2013;172:361-7.
12. Pfeil N, Uhlig U, Kostev K, et al. Antiemetic
medications in children with presumed infectious
gastroenteritis-pharmacoepidemiology
in Europe and Northern America. J Pediatr
2008;153:659-62.
13. Freedman SB, Gouin S, Bhatt M, et al. Prospective
assessment of practice pattern variations
in the treatment of pediatric gastroenteritis.
Pediatrics 2011;127:e287-95.
14. Pelc R, Redant S, Julliand S, Llor J, Lorrot
M, Oostenbrink R, et al. Pediatric gastroenteritis
in the emergency department: practice evaluation
in Belgium, France, The Netherlands
and Switzerland. BMC Pediatr 2014;14:125.
15. DeCamp LR, Byerley JS, Doshi N, Steiner
MJ. Use of antiemetic agents in acute gastroenteritis:
a systematic review and meta-analysis.
Arch Pediatr Adolesc Med 2008;162:
858-65.
16. Howard S. Question 1 Does oral ondansetron
reduce vomiting and the need for intravenous
fluids and hospital admission in children
presenting with vomiting secondary to gastroenteritis?
Arch Dis Child 2010;95:945-7.
17. Fedorowicz Z, Jagannath VA, Carter B. Antiemetics
for reducing vomiting related to acute
ga-stroenteritis in children and adolescents. Cochrane
Database Syst Rev 2011;(9):CD005506.
18. Carter B, Fedorowicz Z. Antiemetic treatment
for acute gastroenteritis in children: an updated
Cochrane systematic review with meta-analysis
and mixed treatment comparison in a
Bayesian framework. BMJ Open 2012;2(4).
19. Das JK, Kumar R, Salam RA, Freedman S,
Bhutta ZA. The effect of antiemetics in
childhood gastroenteritis. BMC Public Health
2013;13(Suppl 3):S9.
20. Rerksuppaphol S, Rerksuppaphol L. Randomized
study of ondansetron versus domperidone
in the treatment of children with acute
gastroenteritis. J Clin Med Res 2013;5:460-6.
21. Van Eygen M, Dhondt F, Heck E, Ameryckx
L, Van Ravensteyn H. A double-blind
comparison of domperidone and metoclopramide
suppositories in the treatment of nausea
and vomiting in children. Postgrad Med J
1979;55(Suppl 1):36-9.
22. Dhondt F, Traen S, VanEygen M, Baran
D, Willaert H. Domperidone (R-33812) suppositories:
an effective antiemetic agent in diverse
pediatric conditions: multicenter trial. Curr
Ther Res Clin Exp 1978;24:912-23.
23. Kita F, Hinotsu S, Yorifuji T, et al. Domperidone
With ORT in the Treatment of Pediatric
Acute Gastroenteritis in Japan: A Multicenter,
Randomized Controlled Trial. Asia Pac J Public
Health 2015;27:NP174-83.
24. Marchetti F, Maestro A, Rovere F, et al. Oral
ondansetron versus domperidone for
symptomatic treatment of vomiting during acute
gastroenteritis in children: multicentre
randomized controlled trial. BMC Pediatr
2011;11:15.
25. Roslund G, Hepps TS, McQuillen KK. The
role of oral ondansetron in children with vomiting
as result of acute gastritis/gastroenteritis
who have failed oral rehydration therapy: a
randomized controlled trial. Ann Emerg Med
2008;52:22-9
26. Freedman SB, Adler M, Seshadri R, Powell
EC. Oral ondansetron for gastroenteritis in a
pediatric emergency department. N Engl J
Med 2006;354:1698-705.
27. Danewa AS, Shah D, Batra P, Bhattacharya
SK, Gupta P. Oral Ondansetron in Management
of Dehydrating Diarrhea with Vomiting
in Children Aged 3 Months to 5 Years: A Randomized
Controlled Trial. J Pediatr 2016;
169:105-9.
28. Ramsook C, Sahagun-Carreon I, Kozinetz
CA, Moro-Sutherland D. A randomized clinical
trial comparing oral ondansetron with placebo
in children with vomiting from acute gastroenteritis.
Ann Emerg Med 2002;39:397-
403.
29. Freedman SB, Uleryk E, Rumantir M,
Finkelstein Y. Ondansetron and the risk of cardiac
arrhythmias: a systematic review and postmarketing
analysis. Ann Emerg Med
2014;64:19-25.
30. Moeller JR, Gummin DD, Nelson TJ, Drendel
AL, Shah BK, Berger S. Risk of Ventricular
Arrhythmias and Association with Ondansetron.
J Pediatr. 2016;179:118-123
31. Roussel V, Tritz T, Souty C, et al. Estimating
the excess of inappropriate prescriptions
of anti-dopaminergic anti-emetics during acute
gastroenteritis epidemics in France. Pharmacoepidemiol
Drug Saf 2013;22:1080-5.
32. EMA. CMDh confirms recommendations
on restricting use of domperidone-containing
medicines. EMA/236452/2014, 25 April 2014.
http://www.ema.europa.eu/docs/en_GB/document_
library/Referrals_document/Domperidone_
31/Position_provided_by_CMDh/
WC500165647.pdf (accessed 13 September
2016).
33. Murgia V, Marchetti F. Domperidone per
la nausea e il vomito: ancora un richiamo alla
limitazione d’uso per effetti collaterali (e mancata
dimostrazione di efficacia). Medico e
Bambino pagine elettroniche 2014;17(5).
34. Marchetti F, Santuccio C, per il gruppo di
lavoro sui Farmaci Pediatrico AIFA. Il Trattamento
farmacologico del vomito: bilancio tra i
rischi e benefici. Bollettino di Informazione sui
Farmaci 2007;5:1-16.
35. Sully BG, Julious SA, Nicholl J. A reinvestigation
of recruitment to randomised, controlled,
multicenter trials: a review of trials funded by
two UK funding agencies. Trials 2013;14:166.
36. Freedman SB, Steiner MJ, Chan KJ. Oral
ondansetron administration in emergency departments
to children with gastroenteritis: an
economic analysis. PLoS Med 2010;7(10).
37. Schnadower D, Finkelstein Y, Freedman
SB. Ondansetron and probiotics in the management
of pediatric acute gastroenteritis in developed
countries. Curr Opin Gastroenterol
2015;31:1-6.
38. Freedman SB, Hall M, Shah SS, et al. Impact
of increasing ondansetron use on clinical
outcomes in children with gastroenteritis. JAMA
Pediatr 2014;168:321-9.
Corrispondenza: luca.ronfani@burlo.trieste.it